Alx Oncology Holdings (ALXO) Research & Development (2019 - 2026)

Alx Oncology Holdings has reported Research & Development for 8 years, with the latest figure at $13.6 million in Q1 2026.

• Quarterly Research & Development fell 43.04% year-over-year to $13.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.7 million (down 38.54% YoY) and the FY2025 annual result came in at $77.0 million, down 33.84% from the prior year.
• Research & Development declined to $13.6 million in Q1 2026 per ALXO's latest filing, from $17.6 million in the prior quarter.
• Over five years, Research & Development peaked at $45.8 million in Q3 2023 and troughed at $13.6 million in Q1 2026.
• A 5-year average of $26.3 million and a median of $25.2 million in 2022 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2025: Research & Development jumped 138.54% in 2022, then slumped 47.99% in 2025.
• Over 5 years, Research & Development stood at $25.2 million in 2022, then surged by 65.83% to $41.8 million in 2023, then slumped by 43.68% to $23.5 million in 2024, then fell by 25.02% to $17.6 million in 2025, then fell by 22.89% to $13.6 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $13.6 million, $17.6 million, and $17.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.